Simplify Asset Management Inc. Purchases 41,315 Shares of Pacira BioSciences, Inc. $PCRX

Posted by George Bondi on May 25th, 2026

Simplify Asset Management Inc. lifted its position in Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report) by 91.9% in the 4th quarter, HoldingsChannel.com reports. The fund owned 86,261 shares of the company’s stock after acquiring an additional 41,315 shares during the quarter. Simplify Asset Management Inc.’s holdings in Pacira BioSciences were worth $2,232,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the stock. LSV Asset Management grew its position in Pacira BioSciences by 179.8% during the fourth quarter. LSV Asset Management now owns 319,800 shares of the company’s stock valued at $8,276,000 after buying an additional 205,500 shares during the period. Global Retirement Partners LLC grew its position in Pacira BioSciences by 479.4% during the fourth quarter. Global Retirement Partners LLC now owns 2,028 shares of the company’s stock valued at $52,000 after buying an additional 1,678 shares during the period. HighTower Advisors LLC grew its position in Pacira BioSciences by 82.0% during the fourth quarter. HighTower Advisors LLC now owns 23,972 shares of the company’s stock valued at $620,000 after buying an additional 10,802 shares during the period. Abacus Wealth Partners LLC bought a new position in Pacira BioSciences during the fourth quarter valued at about $220,000. Finally, Versor Investments LP bought a new position in Pacira BioSciences during the fourth quarter valued at about $489,000. Institutional investors own 99.73% of the company’s stock.

Pacira BioSciences Price Performance

NASDAQ PCRX opened at $23.35 on Monday. The company has a market cap of $918.82 million, a PE ratio of 194.60 and a beta of 0.32. Pacira BioSciences, Inc. has a 52 week low of $18.80 and a 52 week high of $27.64. The company has a quick ratio of 3.35, a current ratio of 4.73 and a debt-to-equity ratio of 0.56. The firm’s 50-day simple moving average is $23.47 and its two-hundred day simple moving average is $23.27.

Pacira BioSciences (NASDAQ:PCRX – Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The company reported $0.60 EPS for the quarter, missing the consensus estimate of $0.61 by ($0.01). The business had revenue of $177.38 million for the quarter, compared to analysts’ expectations of $171.80 million. Pacira BioSciences had a net margin of 0.70% and a return on equity of 10.24%. Pacira BioSciences’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same period last year, the company earned $0.65 earnings per share. Research analysts predict that Pacira BioSciences, Inc. will post 1.91 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Needham & Company LLC increased their price target on shares of Pacira BioSciences from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Friday, May 1st. Zacks Research upgraded shares of Pacira BioSciences from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 7th. Royal Bank Of Canada increased their price target on shares of Pacira BioSciences from $22.00 to $24.00 and gave the company a “sector perform” rating in a research report on Friday, May 1st. Wall Street Zen lowered shares of Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Finally, Barclays reduced their price target on shares of Pacira BioSciences from $27.00 to $25.00 and set an “equal weight” rating for the company in a research report on Thursday, March 26th. Three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $29.40.

View Our Latest Stock Report on Pacira BioSciences

Insider Transactions at Pacira BioSciences

In other news, CFO Shawn Cross sold 12,941 shares of the stock in a transaction dated Thursday, April 23rd. The shares were sold at an average price of $25.16, for a total value of $325,595.56. Following the sale, the chief financial officer directly owned 105,341 shares of the company’s stock, valued at approximately $2,650,379.56. This represents a 10.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jonathan Slonin sold 3,261 shares of the stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $22.82, for a total transaction of $74,416.02. Following the completion of the sale, the insider directly owned 223,640 shares in the company, valued at approximately $5,103,464.80. The trade was a 1.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 28,261 shares of company stock worth $702,610. Insiders own 6.40% of the company’s stock.

Pacira BioSciences Profile

(Free Report)

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.